Selective RET inhibitors shift the treatment pattern of RET fusion-positive NSCLC and improve survival outcomes.

ABSTRACT:

Purpose

Rearranged during transfection (RET) fusions are important genetic drivers in non-small cell lung cancer (NSCLC). Selective RET inhibitors are setting a new paradigm in RET-driven NSCLC. However, the real-world treatment patterns, outcomes and toxicity remain largely unknown.

Methods

Data from RET fusion-positive NSCLC patients treated in our centre were retrospectively analysed. Of them, patients diagnosed before and after August 2018 were included in analysis of treatment patterns; and patients received selective RET inhibitors were eligible for analysis of adverse events (AEs).

Results

Patients diagnosed before August 2018 (n = 30) predominantly received chemotherapy and immunotherapy (83%) as initial therapy, while patients diagnosed after August 2018 (n =

SUBMITTER: Lu C 

PROVIDER: S-EPMC10314840 | biostudies-literature | 2023 Jul

REPOSITORIES: biostudies-literature